Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?

The norms on securing market access are being rewritten for cell and gene therapies.

Fast Track
Accelerated regulatory pathyways can throw up evidentiary challenges for reimbursement • Source: Alamy

Without caution, fast track regulatory paths can be the “route to non-reimbursement” for cell and gene therapies, according to Eric Faulkner, vice president of global real-world-evidence at Novartis Gene Therapies. He advised that to succeed with payers, companies selling cell and gene therapies need to prove transformative effect and think “outside the box” when it comes to generating evidence and communicating with payers.

Novartis Gene Therapies

Novartis is the company behind the gene therapy Zolgesnma (onasemnogene abeparvovec) for the rare disease spinal muscular atrophy. It won approval from the US Food and Drug Administration in May 2019 after being awarded fast track, breakthrough therapy and priority review designations.

It was conditionally approved in the EU in May 2020 after receiving support through the EU’s priority medicines (PRIME) Scheme. Prior to its approval, it was initially accepted for regulatory review under the European Medicines Agency’s accelerated access mechanism but later revered to the standard review timetable.

Novartis also holds the ex-US rights to Luxturna, a gene therapy for inherited retinal dystrophy developed by Spark Theraputics. Luxturna won EU approval in November 2018. It was approved in the US in December 2017 after the FDA granted the application priority review and breakthrough therapy designations.

Securing reimbursement for gene and cell therapies is challenging for a number of reasons, including high prices for products, small...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

Stealth Pushes for Faster US FDA Review Of Barth Syndrome Drug As Funds Dwindle

 
• By 

The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.

New EU Filings

 

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 

Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.

More from Pink Sheet

New EU Filings

 

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight

 
• By 

AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By 

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.